Tuberculosis vaccines and prevention of infection

Microbiology and Molecular Biology Reviews

Volumn 78, Issue 4, 2014, Pages 650-671

  Hawn, Thomas R ^a   Day, Tracey A ^b   Scriba, Thomas J ^c   Hatherill, Mark ^c   Hanekom, Willem A ^c,d   Evans, Thomas G ^e   Churchyard, Gavin J ^f,g   Kublin, James G ^a,b   Bekker, Linda Gail ^c   Self, Steven G ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

^e AERAS   (United States)

^f AURUM INSTITUTE   (South Africa)

^g UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ANIMAL; ANIMAL MODEL; CLINICAL TRIAL (TOPIC); COMPLICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MIXED INFECTION; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; PHYSIOLOGY; THEORETICAL MODEL; TUBERCULOSIS; VACCINATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; COINFECTION; HIV INFECTIONS; HUMANS; MODELS, ANIMAL; MODELS, THEORETICAL; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION;

EID: 84914132771     PISSN: 10922172     EISSN: 10985557     Source Type: Journal    
DOI: 10.1128/MMBR.00021-14     Document Type: Article

References (207)

1. Shenoi S, Friedland G. 2009. Extensively drug-resistant tuberculosis: a new face to an old pathogen. Annu. Rev. Med. 60:307-320. http://dx.doi.org/10.1146/annurev.med.60.053107.103955.
2. Chaisson RE, Martinson NA. 2008. Tuberculosis in Africa - combating an HIV-driven crisis. N. Engl. J. Med. 358:1089-1092. http://dx.doi.org/10.1056/NEJMp0800809.
3. Zumla A, Raviglione M, Hafner R, von Reyn CF. 2013. Tuberculosis. N. Engl. J. Med. 368:745-755. http://dx.doi.org/10.1056/NEJMra1200894.
4. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, Fineberg HV. 1995. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96:29-35.
5. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698-702.
6. Lambert PH, Hawkridge T, Hanekom WA. 2009. New vaccines against tuberculosis. Clin. Chest Med. 30:811-826. http://dx.doi.org/10.1016/j.ccm.2009.08.014.
7. Hussey G, Hawkridge T, Hanekom W. 2007. Childhood tuberculosis: old and new vaccines. Paediatr. Respir. Rev. 8:148-154. http://dx.doi.org/10.1016/j.prrv.2007.04.009.
8. Pitt JM, Blankley S, McShane H, O'Garra A. 2013. Vaccination against tuberculosis: how can we better BCG? Microb. Pathog. 58:2-16. http://dx.doi.org/10.1016/j.micpath.2012.12.002.
9. Meyer J, McShane H. 2013. The next 10 years for tuberculosis vaccines: do we have the right plans in place? Expert Rev. Vaccines 12:443-451. http://dx.doi.org/10.1586/erv.13.19.
10. Ottenhoff TH, Kaufmann SH. 2012. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog. 8:e1002607. http://dx.doi.org/10.1371/journal.ppat.1002607.
11. Brennan MJ, Thole J. 2012. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis 92(Suppl 1):S6-S13. http://dx.doi.org/10.1016/S1472-9792(12)70005-7.
12. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, et al. 2012. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095-2128. http://dx.doi.org/10.1016/S0140-6736(12)61728-0.
13. WHO. 2013. Global tuberculosis report. WHO, Geneva, Switzerland.
14. Rieder HL. 1995. Methodological issues in the estimation of the tuberculosis problem from tuberculin surveys. Tuber. Lung Dis. 76:114-121.
15. Wood R, Liang H, Wu H, Middelkoop K, Oni T, Rangaka MX, Wilkinson RJ, Bekker LG, Lawn SD. 2010. Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. Int. J. Tuberc. Lung Dis. 14:406-412.
16. Jaspan HB, Berwick JR, Myer L, Mathews C, Flisher AJ, Wood R, Bekker LG. 2006. Adolescent HIV prevalence, sexual risk, and willingness to participate in HIV vaccine trials. J. Adolesc. Health 39:642-648. http://dx.doi.org/10.1016/j.jadohealth.2006.05.016.
17. Middelkoop K, Bekker LG, Liang H, Aquino LD, Sebastian E, Myer L, Wood R. 2011. Force of tuberculosis infection among adolescents in a high HIV and TB prevalence community: a cross-sectional observation study. BMC Infect. Dis. 11:156. http://dx.doi.org/10.1186/1471-2334-11-156.
18. Abdool Karim SS, Churchyard GJ, Karim QA, Lawn SD. 2009. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 374:921-933. http://dx.doi.org/10.1016/S0140-6736(09)60916-8.
19. Middelkoop K, Bekker LG, Myer L, Dawson R, Wood R. 2008. Rates of tuberculosis transmission to children and adolescents in a community with a high prevalence of HIV infection among adults. Clin. Infect. Dis. 47:349-355. http://dx.doi.org/10.1086/589750.
20. Nyboe J. 1957. Interpretation of tuberculosis infection age curves. Bull. World Health Organ. 17:319-339.
21. Rieder HL. 1999. Socialization patterns are key to the transmission dynamics of tuberculosis. Int. J. Tuberc. Lung Dis. 3:177-178.
22. Kritzinger FE, den Boon S, Verver S, Enarson DA, Lombard CJ, Borgdorff MW, Gie RP, Beyers N. 2009. No decrease in annual risk of tuberculosis infection in endemic area in Cape Town, South Africa. Trop. Med. Int. Health 14:136-142. http://dx.doi.org/10.1111/j.1365-3156.2008.02213.x.
23. Mahomed H, Ehrlich R, Hawkridge T, Hatherill M, Geiter L, Kafaar F, Abrahams DA, Mulenga H, Tameris M, Geldenhuys H, Hanekom WA, Verver S, Hussey GD. 2013. TB incidence in an adolescent cohort in South Africa. PLoS One 8:e59652. http://dx.doi.org/10.1371/journal.pone.0059652.
24. Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff MW, Enarson DA, Behr MA, van Helden PD. 2005. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am. J. Respir. Crit. Care Med. 171:1430-1435. http://dx.doi.org/10.1164/rccm.200409-1200OC.
25. Middelkoop K, Bekker LG, Shashkina E, Kreiswirth B, Wood R. 2012. Retreatment tuberculosis in a South African community: the role of reinfection, HIV and antiretroviral treatment. Int. J. Tuberc. Lung Dis. 16:1510-1516. http://dx.doi.org/10.5588/ijtld.12.0049.
26. Shanaube K, Sismanidis C, Ayles H, Beyers N, Schaap A, Lawrence KA, Barker A, Godfrey-Faussett P. 2009. Annual risk of tuberculous infection using different methods in communities with a high prevalence of TB and HIV in Zambia and South Africa. PLoS One 4:e7749. http://dx.doi.org/10.1371/journal.pone.0007749.
27. Wiker HG, Mustafa T, Bjune GA, Harboe M. 2010. Evidence for waning of latency in a cohort study of tuberculosis. BMC Infect. Dis. 10:37. http://dx.doi.org/10.1186/1471-2334-10-37.
28. Donald PR. 2004. Childhood tuberculosis: the hidden epidemic. Int. J. Tuberc. Lung Dis. 8:627-629.
29. Donald PR, Marais BJ, Barry CE, III. 2010. Age and the epidemiology and pathogenesis of tuberculosis. Lancet 375:1852-1854. http://dx.doi.org/10.1016/S0140-6736(10)60580-6.
30. Brehony C, Trotter CL, Ramsay ME, Chandra M, Jolley KA, van der Ende A, Carion F, Berthelsen L, Hoffmann S, Harethardottir H, Vazquez JA, Murphy K, Toropainen M, Canica M, Ferreira E, Diggle M, Edwards GF, Taha MK, Stefanelli P, Kriz P, Gray SJ, Fox AJ, Jacobsson S, Claus H, Vogel U, Tzanakaki G, Heuberger S, Caugant DA, Frosch M, Maiden MC. 2014. Implications of differential age distribution of disease-associated meningococcal lineages for vaccine development. Clin. Vaccine Immunol. 21:847-853. http://dx.doi.org/10.1128/CVI.00133-14.
31. Guerra-Silveira F, Abad-Franch F. 2013. Sex bias in infectious disease epidemiology: patterns and processes. PLoS One 8:e62390. http://dx.doi.org/10.1371/journal.pone.0062390.
32. Coler RN, Reed SG. 2005. Second-generation vaccines against leishmaniasis. Trends Parasitol. 21:244-249. http://dx.doi.org/10.1016/j.pt.2005.03.006.
33. Sutherland I. 1968. The ten-year incidence of clinical tuberculosis following "conversion" in 2550 individuals aged 14 to 19 years. KNCV Tuberculosis Foundation, The Hague, The Netherlands.
34. Vynnycky E, Fine PE. 2000. Lifetime risks, incubation period, and serial interval of tuberculosis. Am. J. Epidemiol. 152:247-263. http://dx.doi.org/10.1093/aje/152.3.247.
35. Vynnycky E, Fine PE. 1999. Interpreting the decline in tuberculosis: the role of secular trends in effective contact. Int. J. Epidemiol. 28:327-334. http://dx.doi.org/10.1093/ije/28.2.327.
36. Rieder HL. 1999. Epidemiological basis of tuberculosis control. International Union against Tuberculosis and Lung Disease, Paris, France.
37. van Rie A, Warren R, Richardson M, Victor TC, Gie RP, Enarson DA, Beyers N, van Helden PD. 1999. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N. Engl. J. Med. 341: 1174-1179. http://dx.doi.org/10.1056/NEJM199910143411602.
38. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. 2001. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 358:1687-1693. http://dx.doi.org/10.1016/S0140-6736(01)06712-5.
39. Charalambous S, Grant AD, Moloi V, Warren R, Day JH, van Helden P, Hayes RJ, Fielding KL, De Cock KM, Chaisson RE, Churchyard GJ. 2008. Contribution of reinfection to recurrent tuberculosis in South African gold miners. Int. J. Tuberc. Lung Dis. 12:942-948.
40. 2009. WHO. WHO report: global tuberculosis control: surveillance, planning, financing, global report. World Health Organization, Geneva, Switzerland.
41. Lawn SD, Bekker LG, Middelkoop K, Myer L, Wood R. 2006. Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin. Infect. Dis. 42:1040-1047. http://dx.doi.org/10.1086/501018.
42. City of Cape Town. City of Cape Town HIV, AIDS and TB Plan 2009/2010. http://www.capetown.gov.za.
43. Lawn SD, Fraenzel A, Kranzer K, Caldwell J, Bekker LG, Wood R. 2011. Provider-initiated HIV testing increases access of patients with HIV-associated tuberculosis to antiretroviral treatment. S. Afr. Med. J. 101:258-262.
44. Wood R, Lawn SD, Caldwell J, Kaplan R, Middelkoop K, Bekker LG. 2011. Burden of new and recurrent tuberculosis in a major South African city stratified by age and HIV-status. PLoS One 6:e25098. http://dx.doi.org/10.1371/journal.pone.0025098.
45. Ernst JD. 1998. Macrophage receptors for Mycobacterium tuberculosis. Infect. Immun. 66:1277-1281.
46. Ernst JD. 2012. The immunological life cycle of tuberculosis. Nat. Rev. Immunol. 12:581-591. http://dx.doi.org/10.1038/nri3259.
47. Tailleux L, Maeda N, Nigou J, Gicquel B, Neyrolles O. 2003. How is the phagocyte lectin keyboard played? Master class lesson by Mycobacterium tuberculosis. Trends Microbiol. 11:259-263. http://dx.doi.org/10.1016/S0966-842X(03)00102-1.
48. Tailleux L, Pham-Thi N, Bergeron-Lafaurie A, Herrmann JL, Charles P, Schwartz O, Scheinmann P, Lagrange PH, de Blic J, Tazi A, Gicquel B, Neyrolles O. 2005. DC-SIGN induction in alveolar macrophages defines privileged target host cells for mycobacteria in patients with tuberculosis. PLoS Med. 2:e381. http://dx.doi.org/10.1371/journal.pmed.0020381.
49. Torrelles JB, Azad AK, Henning LN, Carlson TK, Schlesinger LS. 2008. Role of C-type lectins in mycobacterial infections. Curr. Drug Targets 9:102-112. http://dx.doi.org/10.2174/138945008783502467.
50. Ishikawa E, Ishikawa T, Morita YS, Toyonaga K, Yamada H, Takeuchi O, Kinoshita T, Akira S, Yoshikai Y, Yamasaki S. 2009. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J. Exp. Med. 206:2879-2888. http://dx.doi.org/10.1084/jem.20091750.
51. Liu PT, Modlin RL. 2008. Human macrophage host defense against Mycobacterium tuberculosis. Curr. Opin. Immunol. 20:371-376. http://dx.doi.org/10.1016/j.coi.2008.05.014.
52. Russell DG. 2011. Mycobacterium tuberculosis and the intimate discourse of a chronic infection. Immunol. Rev. 240:252-268. http://dx.doi.org/10.1111/j.1600-065X.2010.00984.x.
53. Russell DG, Barry CE, III, Flynn JL. 2010. Tuberculosis: what we don't know can, and does, hurt us. Science 328:852-856. http://dx.doi.org/10.1126/science.1184784.
54. Berrington WR, Hawn TR. 2007. Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter? Immunol. Rev. 219:167-186. http://dx.doi.org/10.1111/j.1600-065X.2007.00545.x.
55. Manzanillo PS, Shiloh MU, Portnoy DA, Cox JS. 2012. Mycobacterium tuberculosis activates the DNA-dependent cytosolic surveillance pathway within macrophages. Cell Host Microbe 11:469-480. http://dx.doi.org/10.1016/j.chom.2012.03.007.
56. Watson RO, Manzanillo PS, Cox JS. 2012. Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell 150: 803-815. http://dx.doi.org/10.1016/j.cell.2012.06.040.
57. Flynn JL. 2006. Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect. 8:1179-1188. http://dx.doi.org/10.1016/j.micinf.2005.10.033.
58. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. 1993. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178:2249-2254. http://dx.doi.org/10.1084/jem.178.6.2249.
59. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. 1993. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J. Exp. Med. 178:2243-2247. http://dx.doi.org/10.1084/jem.178.6.2243.
60. Kagina BM, Abel B, Scriba TJ, Hughes EJ, Keyser A, Soares A, Gamieldien H, Sidibana M, Hatherill M, Gelderbloem S, Mahomed H, Hawkridge A, Hussey G, Kaplan G, Hanekom WA, et al. 2010. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am. J. Respir. Crit. Care Med. 182:1073-1079. http://dx.doi.org/10.1164/rccm.201003-0334OC.
61. Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, Haddix PL, Collins HL, Fok AK, Allen RD, Gluck SL, Heuser J, Russell DG. 1994. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 263:678-681. http://dx.doi.org/10.1126/science.8303277.
62. Pethe K, Swenson DL, Alonso S, Anderson J, Wang C, Russell DG. 2004. Isolation of Mycobacterium tuberculosis mutants defective in the arrest of phagosome maturation. Proc. Natl. Acad. Sci. U. S. A. 101: 13642-13647. http://dx.doi.org/10.1073/pnas.0401657101.
63. Cosma CL, Humbert O, Ramakrishnan L. 2004. Superinfecting mycobacteria home to established tuberculous granulomas. Nat. Immunol.5:828-835. http://dx.doi.org/10.1038/ni1091.
64. Davis JM, Ramakrishnan L. 2009. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 136:37-49. http://dx.doi.org/10.1016/j.cell.2008.11.014.
65. Divangahi M, Desjardins D, Nunes-Alves C, Remold HG, Behar SM. 2010. Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat. Immunol. 11:751-758. http://dx.doi.org/10.1038/ni.1904.
66. Keane J, Remold HG, Kornfeld H. 2000. Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J. Immunol. 164:2016-2020. http://dx.doi.org/10.4049/jimmunol.164.4.2016.
67. Velmurugan K, Chen B, Miller JL, Azogue S, Gurses S, Hsu T, Glickman M, Jacobs WR, Jr, Porcelli SA, Briken V. 2007. Mycobacterium tuberculosis nuoG is a virulence gene that inhibits apoptosis of infected host cells. PLoS Pathog. 3:e110. http://dx.doi.org/10.1371/journal.ppat.0030110.
68. Miller JL, Velmurugan K, Cowan MJ, Briken V. 2010. The type I NADH dehydrogenase of Mycobacterium tuberculosis counters phagosomal NOX2 activity to inhibit TNF-alpha-mediated host cell apoptosis. PLoS Pathog. 6:e1000864. http://dx.doi.org/10.1371/journal.ppat.1000864.
69. Hinchey J, Lee S, Jeon BY, Basaraba RJ, Venkataswamy MM, Chen B, Chan J, Braunstein M, Orme IM, Derrick SC, Morris SL, Jacobs WR, Jr, Porcelli SA. 2007. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J. Clin. Invest. 117:2279-2288. http://dx.doi.org/10.1172/JCI31947.
70. Wolf AJ, Desvignes L, Linas B, Banaiee N, Tamura T, Takatsu K, Ernst JD. 2008. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J. Exp. Med. 205:105-115. http://dx.doi.org/10.1084/jem.20071367.
71. Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM. 2002. Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect. Immun. 70: 4501-4509. http://dx.doi.org/10.1128/IAI.70.8.4501-4509.2002.
72. Flynn KJ, Belz GT, Altman JD, Ahmed R, Woodland DL, Doherty PC. 1998. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 8:683-691. http://dx.doi.org/10.1016/S1074-7613(00)80573-7.
73. Wallgren A. 1948. The time-table of tuberculosis. Tubercle 29:245-251. http://dx.doi.org/10.1016/S0041-3879(48)80033-4.
74. Poulsen A. 1950. Some clinical features of tuberculosis. 1. Incubation period. Acta Tuberc. Scand. 24:311-346.
75. Khader SA, Partida-Sanchez S, Bell G, Jelley-Gibbs DM, Swain S, Pearl JE, Ghilardi N, Desauvage FJ, Lund FE, Cooper AM. 2006. Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. J. Exp. Med. 203:1805-1815. http://dx.doi.org/10.1084/jem.20052545.
76. Reiley WW, Calayag MD, Wittmer ST, Huntington JL, Pearl JE, Fountain JJ, Martino CA, Roberts AD, Cooper AM, Winslow GM, Woodland DL. 2008. ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proc. Natl. Acad. Sci. U. S. A. 105:10961-10966. http://dx.doi.org/10.1073/pnas.0801496105.
77. Pancholi P, Mirza A, Bhardwaj N, Steinman RM. 1993. Sequestration from immune CD4+ T cells of mycobacteria growing in human macrophages. Science 260:984-986. http://dx.doi.org/10.1126/science.8098550.
78. Gallegos AM, Pamer EG, Glickman MS. 2008. Delayed protection by ESAT-6-specific effector CD4+ T cells after airborne M. tuberculosis infection. J. Exp. Med. 205:2359-2368. http://dx.doi.org/10.1084/jem.20080353.
79. Fortune SM, Solache A, Jaeger A, Hill PJ, Belisle JT, Bloom BR, Rubin EJ, Ernst JD. 2004. Mycobacterium tuberculosis inhibits macrophage responses to IFN-gamma through myeloid differentiation factor 88-dependent and -independent mechanisms. J. Immunol. 172:6272-6280. http://dx.doi.org/10.4049/jimmunol.172.10.6272.
80. Kincaid EZ, Ernst JD. 2003. Mycobacterium tuberculosis exerts gene-selective inhibition of transcriptional responses to IFN-gamma without inhibiting STAT1 function. J. Immunol. 171:2042-2049. http://dx.doi.org/10.4049/jimmunol.171.4.2042.
81. Bold TD, Banaei N, Wolf AJ, Ernst JD. 2011. Suboptimal activation of antigen-specific CD4+ effector cells enables persistence of M. tuberculosis in vivo. PLoS Pathog. 7:e1002063. http://dx.doi.org/10.1371/journal.ppat.1002063.
82. Shafiani S, Tucker-Heard G, Kariyone A, Takatsu K, Urdahl KB. 2010. Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J. Exp. Med. 207:1409-1420. http://dx.doi.org/10.1084/jem.20091885.
83. Ordway D, Henao-Tamayo M, Harton M, Palanisamy G, Troudt J, Shanley C, Basaraba RJ, Orme IM. 2007. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J. Immunol. 179:522-531. http://dx.doi.org/10.4049/jimmunol.179.1.522.
84. Cooper AM, Callahan JE, Keen M, Belisle JT, Orme IM. 1997. Expression of memory immunity in the lung following re-exposure to Mycobacterium tuberculosis. Tuber. Lung Dis. 78:67-73. http://dx.doi.org/10.1016/S0962-8479(97)90017-4.
85. Henao-Tamayo MI, Ordway DJ, Irwin SM, Shang S, Shanley C, Orme IM. 2010. Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis. Clin. Vaccine Immunol. 17:618-625. http://dx.doi.org/10.1128/CVI.00368-09.
86. Henao-Tamayo M, Ordway DJ, Orme IM. 2014. Memory T cell subsets in tuberculosis: what should we be targeting? Tuberculosis 94:455-461. http://dx.doi.org/10.1016/j.tube.2014.05.001.
87. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H, MVA85A 020 Trial Study Team. 2013. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381: 1021-1028. http://dx.doi.org/10.1016/S0140-6736(13)60177-4.
88. Tameris M, McShane H, McClain JB, Landry B, Lockhart S, Luabeya AK, Geldenhuys H, Shea J, Hussey G, van der Merwe L, de Kock M, Scriba T, Walker R, Hanekom W, Hatherill M, Mahomed H. 2013. Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. Tuberculosis 93:143-149. http://dx.doi.org/10.1016/j.tube.2013.01.003.
89. Dannenberg AM, Jr. 2010. Perspectives on clinical and preclinical testing of new tuberculosis vaccines. Clin. Microbiol. Rev. 23:781-794. http://dx.doi.org/10.1128/CMR.00005-10.
90. Smith DW, McMurray DN, Wiegeshaus EH, Grover AA, Harding GE. 1970. Host-parasite relationships in experimental airborne tuberculosis. IV. Early events in the course of infection in vaccinated and nonvaccinated guinea pigs. Am. Rev. Respir. Dis. 102:937-949.
91. Riley RL, Mills CC, Nyka W, Weinstock N, Storey PB, Sultan LU, Riley MC, Wells WF. 1995. Aerial dissemination of pulmonary tuberculosis. A two-year study of contagion in a tuberculosis ward. 1959. Am. J. Epidemiol. 142:3-14.
92. Mills CC, O'Grady F, Riley RL. 1960. Tuberculin conversion in the "naturally infected" guinea pig. Bull. Johns Hopkins Hosp. 106:36-45.
93. Dharmadhikari AS, Basaraba RJ, Van Der Walt ML, Weyer K, Mphahlele M, Venter K, Jensen PA, First MW, Parsons S, McMurray DN, Orme IM, Nardell EA. 2011. Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis. Tuberculosis 91:329-338. http://dx.doi.org/10.1016/j.tube.2011.03.002.
94. Riley RL, Mills CC, O'Grady F, Sultan LU, Wittstadt F, Shivpuri DN. 1962. Infectiousness of air from a tuberculosis ward. Ultraviolet irradiation of infected air: comparative infectiousness of different patients. Am. Rev. Respir. Dis. 85:511-525.
95. Escombe AR, Moore DA, Gilman RH, Navincopa M, Ticona E, Mitchell B, Noakes C, Martinez C, Sheen P, Ramirez R, Quino W, Gonzalez A, Friedland JS, Evans CA. 2009. Upper-room ultraviolet light and negative air ionization to prevent tuberculosis transmission. PLoS Med. 6:e43. http://dx.doi.org/10.1371/journal.pmed.1000043.
96. Mahan CS, Zalwango S, Thiel BA, Malone LL, Chervenak KA, Baseke J, Dobbs D, Stein CM, Mayanja H, Joloba M, Whalen CC, Boom WH. 2012. Innate and adaptive immune responses during acute M. tuberculosis infection in adult household contacts in Kampala, Uganda. Am. J. Trop. Med. Hyg. 86:690-697. http://dx.doi.org/10.4269/ajtmh.2012.11-0553.
97. Stein CM, Zalwango S, Malone LL, Won S, Mayanja-Kizza H, Mugerwa RD, Leontiev DV, Thompson CL, Cartier KC, Elston RC, Iyengar SK, Boom WH, Whalen CC. 2008. Genome scan of M. tuberculosis infection and disease in Ugandans. PLoS One 3:e4094. http://dx.doi.org/10.1371/journal.pone.0004094.
98. Guwatudde D, Nakakeeto M, Jones-Lopez EC, Maganda A, Chiunda A, Mugerwa RD, Ellner JJ, Bukenya G, Whalen CC. 2003. Tuberculosis in household contacts of infectious cases in Kampala, Uganda. Am. J. Epidemiol. 158:887-898. http://dx.doi.org/10.1093/aje/kwg227.
99. Guwatudde D, Zalwango S, Kamya MR, Debanne SM, Diaz MI, Okwera A, Mugerwa RD, King C, Whalen CC. 2003. Burden of tuberculosis in Kampala, Uganda. Bull. World Health Organ. 81:799-805.
100. Mayanja-Kizza H, Johnson JL, Hirsch CS, Peters P, Surewicz K, Wu M, Nalugwa G, Mubiru F, Luzze H, Wajja A, Aung H, Ellner JJ, Whalen C, Toossi Z. 2001. Macrophage-activating cytokines in human immununodeficiency virus type 1-infected and -uninfected patients with pulmonary tuberculosis. J. Infect. Dis. 183:1805-1809. http://dx.doi.org/10.1086/320725.
101. Mayanja-Kizza H, Jones-Lopez E, Okwera A, Wallis RS, Ellner JJ, Mugerwa RD, Whalen CC. 2005. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J. Infect. Dis. 191:856-865. http://dx.doi.org/10.1086/427995.
102. Whalen CC. 2005. Diagnosis of latent tuberculosis infection: measure for measure. JAMA 293:2785-2787. http://dx.doi.org/10.1001/jama.293.22.2785.
103. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, Mugerwa RD, Ellner JJ. 1997. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N. Engl. J. Med. 337:801-808.
104. Whalen CC, Zalwango S, Chiunda A, Malone L, Eisenach K, Joloba M, Boom WH, Mugerwa R. 2011. Secondary attack rate of tuberculosis in urban households in Kampala, Uganda. PLoS One 6:e16137. http://dx.doi.org/10.1371/journal.pone.0016137.
105. Lancioni C, Nyendak M, Kiguli S, Zalwango S, Mori T, Mayanja-Kizza H, Balyejusa S, Null M, Baseke J, Mulindwa D, Byrd L, Swarbrick G, Scott C, Johnson DF, Malone L, Mudido-Musoke P, Boom WH, Lewinsohn DM, Lewinsohn DA. 2012. CD8+ T cells provide an immunologic signature of tuberculosis in young children. Am. J. Respir. Crit. Care Med. 185:206-212. http://dx.doi.org/10.1164/rccm.201107-1355OC.
106. Cobat A, Gallant CJ, Simkin L, Black GF, Stanley K, Hughes J, Doherty TM, Hanekom WA, Eley B, Jais JP, Boland-Auge A, van Helden P, Casanova JL, Abel L, Hoal EG, Schurr E, Alcais A. 2009. Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. J. Exp. Med. 206:2583-2591. http://dx.doi.org/10.1084/jem.20090892.
107. Hawn TR, Matheson AI, Maley SN, Vandal O. 2013. Host-directed therapeutics for tuberculosis: can we harness the host? Microbiol. Mol. Biol. Rev. 77:608-627. http://dx.doi.org/10.1128/MMBR.00032-13.
108. Bjartveit K. 2003. Olaf Scheel and Johannes Heimbeck: their contribution to understanding the pathogenesis and prevention of tuberculosis. Int. J. Tuberc. Lung Dis. 7:306-311.
109. Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR. 2012. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin. Infect. Dis. 54:784-791. http://dx.doi.org/10.1093/cid/cir951.
110. Machingaidze S, Verver S, Mulenga H, Abrahams DA, Hatherill M, Hanekom W, Hussey GD, Mahomed H. 2012. Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents. Am. J. Respir. Crit. Care Med. 186:1051-1056. http://dx.doi.org/10.1164/rccm.201206-1134OC.
111. Mahomed H, Hawkridge T, Verver S, Abrahams D, Geiter L, Hatherill M, Ehrlich R, Hanekom WA, Hussey GD. 2011. The tuberculin skin test versus QuantiFERON TB Gold(R) in predicting tuberculosis disease in an adolescent cohort study in South Africa. PLoS One 6:e17984. http://dx.doi.org/10.1371/journal.pone.0017984.
112. Brooks-Pollock E, Becerra MC, Goldstein E, Cohen T, Murray MB. 2011. Epidemiologic inference from the distribution of tuberculosis cases in households in Lima, Peru. J. Infect. Dis. 203:1582-1589. http://dx.doi.org/10.1093/infdis/jir162.
113. Adams JM, Kalajan VA, Mork BO, Rosenblatt M, Rothrock WJ, O'Loughlin BJ. 1959. Reversal of tuberculin reaction in early tuberculosis. Dis. Chest 35:348-356. http://dx.doi.org/10.1378/chest.35.4.348.
114. Gelien J, Hamman L. 1913. The subsequent history of 1000 patients who recieved tuberculin tests. Bull. Johns Hopkins Hosp. 24:180-186.
115. Fine PE, Bruce J, Ponnighaus JM, Nkhosa P, Harawa A, Vynnycky E. 1999. Tuberculin sensitivity: conversions and reversions in a rural African population. Int. J. Tuberc. Lung Dis. 3:962-975.
116. Dahlstrom A. 1940. The instability of the tuberculin reaction. Am. Rev. Tuberc. 42:471-487.
117. Hill PC, Brookes RH, Fox A, Jackson-Sillah D, Jeffries DJ, Lugos MD, Donkor SA, Adetifa IM, de Jong BC, Aiken AM, Adegbola RA, Mc-Adam KP. 2007. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med. 4:e192. http://dx.doi.org/10.1371/journal.pmed.0040192.
118. Gordin FM, Perez-Stable EJ, Reid M, Schecter G, Cosgriff L, Flaherty D, Hopewell PC. 1991. Stability of positive tuberculin tests: are boosted reactions valid? Am. Rev. Respir. Dis. 144:560-563. http://dx.doi.org/10.1164/ajrccm/144.3-Pt-1.560.
119. Shah M, Kasambira TS, Adrian PV, Madhi SA, Martinson NA, Dorman SE. 2011. Longitudinal analysis of QuantiFERON-TB Gold In-Tube in children with adult household tuberculosis contact in South Africa: a prospective cohort study. PLoS One 6:e26787. http://dx.doi.org/10.1371/journal.pone.0026787.
120. Andersen P, Doherty TM. 2005. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3:656-662. http://dx.doi.org/10.1038/nrmicro1211.
121. Riley RL. 1957. Aerial dissemination of pulmonary tuberculosis. Am. Rev. Tuberc. 76:931-941.
122. Saini D, Hopkins GW, Seay SA, Chen CJ, Perley CC, Click EM, Frothingham R. 2012. Ultra-low dose of Mycobacterium tuberculosis aerosol creates partial infection in mice. Tuberculosis 92:160-165. http://dx.doi.org/10.1016/j.tube.2011.11.007.
123. Ordway D, Henao-Tamayo M, Shanley C, Smith EE, Palanisamy G, Wang B, Basaraba RJ, Orme IM. 2008. Influence of Mycobacterium bovis BCG vaccination on cellular immune response of guinea pigs challenged with Mycobacterium tuberculosis. Clin. Vaccine Immunol. 15:1248-1258. http://dx.doi.org/10.1128/CVI.00019-08.
124. Mittrucker HW, Steinhoff U, Kohler A, Krause M, Lazar D, Mex P, Miekley D, Kaufmann SH. 2007. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 104:12434-12439. http://dx.doi.org/10.1073/pnas.0703510104.
125. Grover A, Taylor J, Troudt J, Keyser A, Arnett K, Izzo L, Rholl D, Izzo A. 2009. Kinetics of the immune response profile in guinea pigs after vaccination with Mycobacterium bovis BCG and infection with Mycobacterium tuberculosis. Infect. Immun. 77:4837-4846. http://dx.doi.org/10.1128/IAI.00704-09.
126. Smith DW, Wiegeshaus E, Navalkar R, Grover AA. 1966. Host-parasite relationships in experimental airborne tuberculosis. I. Preliminary studies in BCG-vaccinated and nonvaccinated animals. J. Bacteriol. 91:718-724.
127. McMurray DN. 2000. A nonhuman primate model for preclinical testing of new tuberculosis vaccines. Clin. Infect. Dis. 30(Suppl 3):S210-S212. http://dx.doi.org/10.1086/313885.
128. McMurray DN. 2003. Hematogenous reseeding of the lung in low-dose, aerosol-infected guinea pigs: unique features of the host-pathogen interface in secondary tubercles. Tuberculosis 83:131-134. http://dx.doi.org/10.1016/S1472-9792(02)00079-3.
129. Cohn ML, Davis CL, Middlebrook G. 1958. Airborne immunization against tuberculosis. Science 128:1282-1283. http://dx.doi.org/10.1126/science.128.3334.1282.
130. Janicki BW, Good RC, Minden P, Affronti LF, Hymes WF. 1973. Immune responses in rhesus monkeys after bacillus Calmette-Guerin vaccination and aerosol challenge with Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 107:359-366.
131. Barclay WR, Busey WM, Dalgard DW, Good RC, Janicki BW, Kasik JE, Ribi E, Ulrich CE, Wolinsky E. 1973. Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guerin. Am. Rev. Respir. Dis. 107:351-358.
132. Capuano SV, III, Croix DA, Pawar S, Zinovik A, Myers A, Lin PL, Bissel S, Fuhrman C, Klein E, Flynn JL. 2003. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect. Immun. 71:5831-5844. http://dx.doi.org/10.1128/IAI.71.10.5831-5844.2003.
133. Barclay WR, Anacker RL, Brehmer W, Leif W, Ribi E. 1970. Aerosol-induced tuberculosis in subhuman primates and the course of the disease after intravenous BCG vaccination. Infect. Immun. 2:574-582.
134. Gormus BJ, Blanchard JL, Alvarez XH, Didier PJ. 2004. Evidence for a rhesus monkey model of asymptomatic tuberculosis. J. Med. Primatol. 33:134-145. http://dx.doi.org/10.1111/j.1600-0684.2004.00062.x.
135. Walsh GP, Tan EV, dela Cruz EC, Abalos RM, Villahermosa LG, Young LJ, Cellona RV, Nazareno JB, Horwitz MA. 1996. The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat. Med. 2:430-436. http://dx.doi.org/10.1038/nm0496-430.
136. Langermans JA, Andersen P, van Soolingen D, Vervenne RA, Frost PA, van der Laan T, van Pinxteren LA, van den Hombergh J, Kroon S, Peekel I, Florquin S, Thomas AW. 2001. Divergent effect of bacillus Calmette-Guerin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. Proc. Natl. Acad. Sci. U. S. A. 98: 11497-11502. http://dx.doi.org/10.1073/pnas.201404898.
137. Sharpe SA, McShane H, Dennis MJ, Basaraba RJ, Gleeson F, Hall G, McIntyre A, Gooch K, Clark S, Beveridge NE, Nuth E, White A, Marriott A, Dowall S, Hill AV, Williams A, Marsh PD. 2010. Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing. Clin. Vaccine Immunol. 17:1170-1182. http://dx.doi.org/10.1128/CVI.00079-10.
138. Mehra S, Alvarez X, Didier PJ, Doyle LA, Blanchard JL, Lackner AA, Kaushal D. 2013. Granuloma correlates of protection against tuberculosis and mechanisms of immune modulation by Mycobacterium tuberculosis. J. Infect. Dis. 207:1115-1127. http://dx.doi.org/10.1093/infdis/jis778.
139. Berggren SA. 1981. Field experiment with BCG vaccine in Malawi. Br. Vet. J. 137:88-96.
140. Berggren SA. 1977. Incidence of tuberculosis in BCG vaccinated and control cattle in relation to age distribution in Malawi. Br. Vet. J. 133: 490-494.
141. Ellwood DC, Waddington FG. 1972. A second experiment to challenge the resistance to tuberculosis in B.C.G. vaccinated cattle in Malawi. Br. Vet. J. 128:619-626.
142. Ellwood DC. 1975. First results of the field use of BCG vaccine to control bovine tuberculosis in Malawi. Br. Vet. J. 131:186-189.
143. Waddington FG, Ellwood DC. 1972. An experiment to challenge the resistance to tuberculosis in B.C.G. vaccinated cattle in Malawi. Br. Vet. J. 128:541-552.
144. Griffin JF. 2000. Veterinary tuberculosis vaccine development. Clin. Infect. Dis. 30(Suppl 3):S223-228. http://dx.doi.org/10.1086/313865.
145. Hope JC, Thom ML, Villarreal-Ramos B, Vordermeier HM, Hewinson RG, Howard CJ. 2005. Vaccination of neonatal calves with Mycobacterium bovis BCG induces protection against intranasal challenge with virulent M. bovis. Clin. Exp. Immunol. 139:48-56. http://dx.doi.org/10.1111/j.1365-2249.2005.02668.x.
146. Buddle BM, Keen D, Thomson A, Jowett G, McCarthy AR, Heslop J, De Lisle GW, Stanford JL, Aldwell FE. 1995. Protection of cattle from bovine tuberculosis by vaccination with BCG by the respiratory or subcutaneous route, but not by vaccination with killed Mycobacterium vaccae. Res. Vet. Sci. 59: 10-16. http://dx.doi.org/10.1016/0034-5288(95)90023-3.
147. Buddle BM, de Lisle GW, Pfeffer A, Aldwell FE. 1995. Immunological responses and protection against Mycobacterium bovis in calves vaccinated with a low dose of BCG. Vaccine 13:1123-1130. http://dx.doi.org/10.1016/0264-410X(94)00055-R.
148. Vordermeier HM, Chambers MA, Cockle PJ, Whelan AO, Simmons J, Hewinson RG. 2002. Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis. Infect. Immun. 70:3026-3032. http://dx.doi.org/10.1128/IAI.70.6.3026-3032.2002.
149. Wedlock DN, Denis M, Vordermeier HM, Hewinson RG, Buddle BM. 2007. Vaccination of cattle with Danish and Pasteur strains of Mycobacterium bovis BCG induce different levels of IFNgamma post-vaccination, but induce similar levels of protection against bovine tuberculosis. Vet. Immunol. Immunopathol. 118:50-58. http://dx.doi.org/10.1016/j.vetimm.2007.04.005.
150. Vordermeier HM, Villarreal-Ramos B, Cockle PJ, McAulay M, Rhodes SG, Thacker T, Gilbert SC, McShane H, Hill AV, Xing Z, Hewinson RG. 2009. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect. Immun. 77:3364-3373. http://dx.doi.org/10.1128/IAI.00287-09.
151. Griffin JF, Mackintosh CG, Slobbe L, Thomson AJ, Buchan GS. 1999. Vaccine protocols to optimise the protective efficacy of BCG. Tuber. Lung Dis. 79:135-143. http://dx.doi.org/10.1054/tuld.1998.0202.
152. Griffin JF, Mackintosh CG, Rodgers CR. 2006. Factors influencing the protective efficacy of a BCG homologous prime-boost vaccination regime against tuberculosis. Vaccine 24:835-845. http://dx.doi.org/10.1016/j.vaccine.2005.07.033.
153. Ameni G, Vordermeier M, Aseffa A, Young DB, Hewinson RG. 2010. Field evaluation of the efficacy of Mycobacterium bovis bacillus Calmette-Guerin against bovine tuberculosis in neonatal calves in Ethiopia. Clin. Vaccine Immunol. 17:1533-1538. http://dx.doi.org/10.1128/CVI.00222-10.
154. Lopez-Valencia G, Renteria-Evangelista T, Williams Jde J, Licea-Navarro A, Mora-Valle Ade L, Medina-Basulto G. 2010. Field evaluation of the protective efficacy of Mycobacterium bovis BCG vaccine against bovine tuberculosis. Res. Vet. Sci. 88:44-49. http://dx.doi.org/10.1016/j.rvsc.2009.05.022.
155. Carter SP, Chambers MA, Rushton SP, Shirley MD, Schuchert P, Pietravalle S, Murray A, Rogers F, Gettinby G, Smith GC, Delahay RJ, Hewinson RG, McDonald RA. 2012. BCG vaccination reduces risk of tuberculosis infection in vaccinated badgers and unvaccinated badger cubs. PLoS One 7:e49833. http://dx.doi.org/10.1371/journal.pone.0049833.
156. Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, Snell L, Mangtani P, Adetifa I, Lalvani A, Abubakar I. 2014. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ 349:g4643. http://dx.doi.org/10.1136/bmj.g4643.
157. Basu Roy R, Sotgiu G, Altet-Gomez N, Tsolia M, Ruga E, Velizarova S, Kampmann B. 2012. Identifying predictors of interferon-gamma release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmette-Guerin? A pTB-NET collaborative study. Am. J. Respir. Crit. Care Med. 186:378-384. http://dx.doi.org/10.1164/rccm.201201-0026OC.
158. Michelsen SW, Soborg B, Koch A, Carstensen L, Hoff ST, Agger EM, Lillebaek T, Sorensen HC, Wohlfahrt J, Melbye M. 2014. The effectiveness of BCG vaccination in preventing Mycobacterium tuberculosis infection and disease in Greenland. Thorax 69:851-856. http://dx.doi.org/10.1136/thoraxjnl-2014-205688.
159. Hart PD, Sutherland I. 1972. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Bull. World Health Organ. 46:371-385.
160. Tuberculosis Research Center. 2013. Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. 1999. Indian J. Med. Res. 137:14 p following p571.
161. Karonga Prevention Trials Group. 1996. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet 348:17-24.
162. Black GF, Dockrell HM, Crampin AC, Floyd S, Weir RE, Bliss L, Sichali L, Mwaungulu L, Kanyongoloka H, Ngwira B, Warndorff DK, Fine PE. 2001. Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in northern Malawi. J. Infect. Dis. 184:322-329. http://dx.doi.org/10.1086/322042.
163. Black GF, Weir RE, Floyd S, Bliss L, Warndorff DK, Crampin AC, Ngwira B, Sichali L, Nazareth B, Blackwell JM, Branson K, Chaguluka SD, Donovan L, Jarman E, King E, Fine PE, Dockrell HM. 2002. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 359:1393-1401. http://dx.doi.org/10.1016/S0140-6736(02)08353-8.
164. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM, Jr, Dye C, Halloran ME. 2009. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc. Natl. Acad. Sci. U. S. A. 106: 13980-13985. http://dx.doi.org/10.1073/pnas.0901720106.
165. Halloran ME, Longini IM, Struchiner CJ. 2010. Design and analysis of vaccine studies. Springer, New York, NY.
166. Rustomjee R, McClain B, Brennan MJ, McLeod R, Chetty-Makkan CM, McShane H, Hanekom W, Steel G, Mahomed H, Ginsberg AM, Shea J, Lockhart S, Self S, Churchyard GJ. 2013. Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents. Tuberculosis 93:136-142. http://dx.doi.org/10.1016/j.tube.2012.11.005.
167. Van Rhijn I, Ly D, Moody DB. 2013. CD1a, CD1b, and CD1c in immunity against mycobacteria. Adv. Exp. Med. Biol. 783:181-197. http://dx.doi.org/10.1007/978-1-4614-6111-1-10.
168. Williams A, Reljic R, Naylor I, Clark SO, Falero-Diaz G, Singh M, Challacombe S, Marsh PD, Ivanyi J. 2004. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology 111:328-333. http://dx.doi.org/10.1111/j.1365-2567.2004.01809.x.
169. Sebina I, Cliff JM, Smith SG, Nogaro S, Webb EL, Riley EM, Dockrell HM, Elliott AM, Hafalla JC, Cose S. 2012. Long-lived memory B-cell responses following BCG vaccination. PLoS One 7:e51381. http://dx.doi.org/10.1371/journal.pone.0051381.
170. Kozakiewicz L, Chen Y, Xu J, Wang Y, Dunussi-Joannopoulos K, Ou Q, Flynn JL, Porcelli SA, Jacobs WR, Jr, Chan J. 2013. B cells regulate neutrophilia during Mycobacterium tuberculosis infection and BCG vaccination by modulating the interleukin-17 response. PLoS Pathog. 9:e1003472. http://dx.doi.org/10.1371/journal.ppat.1003472.
171. Kondratieva TK, Rubakova EI, Linge IA, Evstifeev VV, Majorov KB, Apt AS. 2010. B cells delay neutrophil migration toward the site of stimulus: tardiness critical for effective bacillus Calmette-Guerin vaccination against tuberculosis infection in mice. J. Immunol. 184:1227-1234. http://dx.doi.org/10.4049/jimmunol.0902011.
172. Achkar JM, Casadevall A. 2013. Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe 13:250-262. http://dx.doi.org/10.1016/j.chom.2013.02.009.
173. Turner J, Frank AA, Brooks JV, Gonzalez-Juarrero M, Orme IM. 2001. The progression of chronic tuberculosis in the mouse does not require the participation of B lymphocytes or interleukin-4. Exp. Gerontol. 36:537-545. http://dx.doi.org/10.1016/S0531-5565(00)00257-6.
174. Johnson CM, Cooper AM, Frank AA, Bonorino CB, Wysoki LJ, Orme IM. 1997. Mycobacterium tuberculosis aerogenic rechallenge infections in B cell-deficient mice. Tuber. Lung Dis. 78:257-261. http://dx.doi.org/10.1016/S0962-8479(97)90006-X.
175. Churchyard GJ, Fielding KL, Lewis JJ, Coetzee L, Corbett EL, Godfrey-Faussett P, Hayes RJ, Chaisson RE, Grant AD, Thibela TBST. 2014. A trial of mass isoniazid preventive therapy for tuberculosis control. N. Engl. J. Med. 370:301-310. http://dx.doi.org/10.1056/NEJMoa1214289.
176. Lachenbruch PA. 1998. Sensitivity, specificity, and vaccine efficacy. Controlled Clin. Trials 19:569-574. http://dx.doi.org/10.1016/S0197-2456(98)00042-7.
177. Grode L, Ganoza CA, Brohm C, JWeiner 3rd, Eisele B, Kaufmann SH. 2013. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine 31:1340-1348. http://dx.doi.org/10.1016/j.vaccine.2012.12.053.
178. Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser Eddine A, Mann P, Goosmann C, Bandermann S, Smith D, Bancroft GJ, Reyrat JM, van Soolingen D, Raupach B, Kaufmann SH. 2005. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J. Clin. Invest. 115:2472-2479. http://dx.doi.org/10.1172/JCI24617.
179. Cardona PJ. 2006. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis 86:273-289. http://dx.doi.org/10.1016/j.tube.2006.01.024.
180. Vilaplana C, Gil O, Caceres N, Pinto S, Diaz J, Cardona PJ. 2011. Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis. PLoS One 6:e20404. http://dx.doi.org/10.1371/journal.pone.0020404.
181. de Bruyn G, Garner P. 2003. Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database Syst. Rev. 2003:CD001166.
182. Katoch K, Singh P, Adhikari T, Benara SK, Singh HB, Chauhan DS, Sharma VD, Lavania M, Sachan AS, Katoch VM. 2008. Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. Vaccine 26: 1228-1234. http://dx.doi.org/10.1016/j.vaccine.2007.12.025.
183. Martin C, Williams A, Hernandez-Pando R, Cardona PJ, Gormley E, Bordat Y, Soto CY, Clark SO, Hatch GJ, Aguilar D, Ausina V, Gicquel B. 2006. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 24:3408-3419. http://dx.doi.org/10.1016/j.vaccine.2006.03.017.
184. von Reyn CF, Mtei L, Arbeit RD, Waddell R, Cole B, Mackenzie T, Matee M, Bakari M, Tvaroha S, Adams LV, Horsburgh CR, Pallangyo K, DarDar Study G. 2010. Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 24:675-685. http://dx.doi.org/10.1097/QAD.0b013e3283350f1b.
185. Lahey T, Arbeit RD, Bakari M, Horsburgh CR, Matee M, Waddell R, Mtei L, Vuola JM, Pallangyo K, von Reyn CF. 2010. Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania. Vaccine 28:7652-7658. http://dx.doi.org/10.1016/j.vaccine.2010.09.041.
186. Harris SA, Meyer J, Satti I, Marsay L, Poulton ID, Tanner R, Minassian AM, Fletcher HA, McShane H. 2014. Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination. J. Infect. Dis. 209:1259-1268. http://dx.doi.org/10.1093/infdis/jit647.
187. Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Mauff K, Hughes EJ, Moyo S, Brittain N, Lawrie A, Mulenga H, de Kock M, Gelderbloem S, Veldsman A, Hatherill M, Geldenhuys H, Hill AV, Hussey GD, Mahomed H, Hanekom WA, McShane H. 2011. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J. Infect. Dis. 203:1832-1843. http://dx.doi.org/10.1093/infdis/jir195.
188. Radosevic K, Wieland CW, Rodriguez A, Weverling GJ, Mintardjo R, Gillissen G, Vogels R, Skeiky YA, Hone DM, Sadoff JC, van der Poll T, Havenga M, Goudsmit J. 2007. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect. Immun. 75:4105-4115. http://dx.doi.org/10.1128/IAI.00004-07.
189. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, Zganiacz A, Hitt M, Xing Z. 2004. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. 173:6357-6365. http://dx.doi.org/10.4049/jimmunol.173.10.6357.
190. Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z. 2006. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun. 74:4634-4643. http://dx.doi.org/10.1128/IAI.00517-06.
191. Montoya J, Solon JA, Cunanan SR, Acosta L, Bollaerts A, Moris P, Janssens M, Jongert E, Demoitie MA, Mettens P, Gatchalian S, Vinals C, Cohen J, Ofori-Anyinam O. 2013. A randomized, controlled dose-finding phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults. J. Clin. Immunol. 33:1360-1375. http://dx.doi.org/10.1007/s10875-013-9949-3.
192. Day CL, Tameris M, Mansoor N, van Rooyen M, de Kock M, Geldenhuys H, Erasmus M, Makhethe L, Hughes EJ, Gelderbloem S, Bollaerts A, Bourguignon P, Cohen J, Demoitie MA, Mettens P, Moris P, Sadoff JC, Hawkridge A, Hussey GD, Mahomed H, Ofori-Anyinam O, Hanekom WA. 2013. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Am. J. Respir. Crit. Care Med. 188:492-502. http://dx.doi.org/10.1164/rccm.201208-1385OC.
193. Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P. 2001. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and Esat-6. Infect. Immun. 69:2773-2778. http://dx.doi.org/10.1128/IAI.69.5.2773-2778.2001.
194. Langermans JA, Doherty TM, Vervenne RA, van der Laan T, Lyashchenko K, Greenwald R, Agger EM, Aagaard C, Weiler H, van Soolingen D, Dalemans W, Thomas AW, Andersen P. 2005. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23:2740-2750. http://dx.doi.org/10.1016/j.vaccine.2004.11.051.
195. Hoang T, Aagaard C, Dietrich J, Cassidy JP, Dolganov G, Schoolnik GK, Lundberg CV, Agger EM, Andersen P. 2013. ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination. PLoS One 8:e80579. http://dx.doi.org/10.1371/journal.pone.0080579.
196. Billeskov R, Elvang TT, Andersen PL, Dietrich J. 2012. The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS One 7:e39909. http://dx.doi.org/10.1371/journal.pone.0039909.
197. Elvang T, Christensen JP, Billeskov R, Thi Kim Thanh Hoang T, Holst P, Thomsen AR, Andersen P, Dietrich J. 2009. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. PLoS One 4:e5139. http://dx.doi.org/10.1371/journal.pone.0005139.
198. Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, Andersen P. 2011. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat. Med. 17:189-194. http://dx.doi.org/10.1038/nm.2285.
199. Lin PL, Dietrich J, Tan E, Abalos RM, Burgos J, Bigbee C, Bigbee M, Milk L, Gideon HP, Rodgers M, Cochran C, Guinn KM, Sherman DR, Klein E, Janssen C, Flynn JL, Andersen P. 2012. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J. Clin. Invest. 122:303-314. http://dx.doi.org/10.1172/JCI46252.
200. Orr MT, Beebe EA, Hudson TE, Moon JJ, Fox CB, Reed SG, Coler RN. 2014. A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93. PLoS One 9:e83884. http://dx.doi.org/10.1371/journal.pone.0083884.
201. Baldwin SL, Ching LK, Pine SO, Moutaftsi M, Lucas E, Vallur A, Orr MT, Bertholet S, Reed SG, Coler RN. 2013. Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells. J. Immunol. 191:2514-2525. http://dx.doi.org/10.4049/jimmunol.1301161.
202. Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M, Phan T, Orme IM, Vedvick TS, Baldwin SL, Coler RN, Reed SG. 2010. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci. Transl. Med. 2:53ra74. http://dx.doi.org/10.1126/scitranslmed.3001094.
203. Aronson JD. 1951. The fluctuation of the tuberculin reaction in different geographic areas and its relationship to resistance. Am. Rev. Tuberc. 63:121-139.
204. Perez-Stable EJ, Flaherty D, Schecter G, Slutkin G, Hopewell PC. 1988. Conversion and reversion of tuberculin reactions in nursing home residents. Am. Rev. Respir. Dis. 137:801-804. http://dx.doi.org/10.1164/ajrccm/137.4.801.
205. Soysal A, Millington KA, Bakir M, Dosanjh D, Aslan Y, Deeks JJ, Efe S, Staveley I, Ewer K, Lalvani A. 2005. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 366: 1443-1451. http://dx.doi.org/10.1016/S0140-6736(05)67534-4.
206. Hill PC, Brookes RH, Adetifa IM, Fox A, Jackson-Sillah D, Lugos MD, Donkor SA, Marshall RJ, Howie SR, Corrah T, Jeffries DJ, Adegbola RA, McAdam KP. 2006. Comparison of enzyme-linked immunospot assay and tuberculin skin test in healthy children exposed to Mycobacterium tuberculosis. Pediatrics 117:1542-1548. http://dx.doi.org/10.1542/peds.2005-2095.
207. Lucas M, Nicol P, McKinnon E, Whidborne R, Lucas A, Thambiran A, Burgner D, Waring J, French M. 2010. A prospective large-scale study of methods for the detection of latent Mycobacterium tuberculosis infection in refugee children. Thorax 65:442-448. http://dx.doi.org/10.1136/thx.2009.127555.